SPECT/CT

Spectrum Dynamics is proud to announce the Installation of the VERITON-CT SPECT/CT imaging system at European Leading Cancer Center, Gustave Roussy

Retrieved on: 
Thursday, March 21, 2024
Toxicity, CZT, Algorithm, Patient, Neoplasm, Hospital, 3D, Cancer, Gustave Roussy, Google Images, The, SPECT, SPECT/CT, Newsweek, Nuclear medicine, Health, Medical imaging

Gustave Roussy is considered as a leading cancer centre in Europe.

Key Points: 
  • Gustave Roussy is considered as a leading cancer centre in Europe.
  • The institute treats patients with all types of cancer at any age and is a leading institution in the treatment of rare and complex tumors.
  • It is unlike any other ring-shaped gantry, with a 360o CZT 12-detector design that automatically moves close to the patient's body.
  • "We are delighted to collaborate with Gustav Roussy with the install of the VERITON-CT 400 SPECT/CT scanner," says Johann Fernando, Executive Vice President, Spectrum Dynamics.

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Retrieved on: 
Monday, March 4, 2024
Head, Neck, Recurrence, Toxicity, Anemia, Completeness, Radiation, SPECT/CT, Chemoradiotherapy, EBRT, Macroglobulinemia, Lymphocytopenia, Thrombocytopenia, Patient, Neutropenia, Survival, Poster, Cytopenia, Cancer, Pharmaceutical industry

The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).

Key Points: 
  • The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradiation alone (42%), surgery (58%) or surgery combined with radiation or chemoradiation (92%).
  • The data were presented in a poster at the 2024 Multidisciplinary Head and Neck Cancers Symposium held February 29-March 2, 2024, in Phoenix, AZ.
  • Complete remission was achieved in 64% of patients, with an ORR of 73% (n=11).
  • Observed adverse events were consistent with the known toxicity profile of iopofosine I 131, with cytopenias being the most common with all patients recovering.

Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Retrieved on: 
Tuesday, November 28, 2023
Molecular imaging, SSTR2, Food, Perspective, NET, Physician, Nuclear medicine, PET/CT, SPECT/CT, Patient safety, NETS, Half-life, Therapy, Liver disease, Neoplasm, Isotope, Noise, Siemens Healthineers, Patient, CATX, Diagnosis, SPECT, European Journal, Institute of technology, DOTATATE, Glomus tumor, Medical imaging

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images utilizing the alpha-emitting isotope of 212Pb, which was labeled to the Company’s proprietary theranostic VMT-α-NET product. The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany. The Company is developing VMT-α-NET for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors.

Key Points: 
  • The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany.
  • VMT-α-NET is being administered under the supervision of Prof. Dr. Jörg Kotzerke, Director of the Department of Nuclear Medicine at the Technical University of Dresden in Germany.
  • The SPECT/CT images showed high accumulation of [212Pb]VMT-α-NET in liver metastases and were consistent with the previously acquired [68Ga]DOTATATE PET/CT.
  • Perspective Therapeutics supplies a generator, drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-α-NET.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Expanding the Reach of Care for Cancer and Other Disease States: BAMF Health and GE HealthCare collaborate to enable sustainable and scalable solutions for growth in Theranostics

Retrieved on: 
Monday, November 13, 2023
Other Health, Software, General Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Other Technology, Health, BAMF, PET/CT, SPECT/CT, PET/MR, Patient, Multimedia, Alzheimer's disease, Molecular imaging, Cyclotron, Cancer, Drug development, GE HealthCare, Medical imaging, Personalized medicine

As demand for Theranostic care increases, GE HealthCare and BAMF Health are excited to announce a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services.

Key Points: 
  • As demand for Theranostic care increases, GE HealthCare and BAMF Health are excited to announce a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services.
  • The goal of the collaboration is to ensure an agile go-to-market approach to enhance the adoption of Theranostics solutions in the U.S.
  • The arrangement supports a shared interest in better patient outcomes made possible through advanced diagnostics and radiotherapeutics.
  • The collaboration between GE HealthCare and BAMF Health will leverage both partners’ deep understanding of the complexities of delivering Theranostic care to establish a framework to support the scalable infrastructure and clinical solutions for expanded adoption of precision care.

Convergent Imaging Solutions announces public tender win for nuclear medicine workstations in home base of Ottawa, Ontario

Retrieved on: 
Thursday, July 13, 2023
Enterprise, Agfa-Gevaert, Therapy, Workflow, Syntermes, Deep learning, Cedars, Convergent, DICOM, Sale, Imaging, Cedars-Sinai Medical Center, Nuclear medicine, Physician, Molecular imaging, PET/CT, SPECT/CT, FDA, Health Canada, Software, Medical imaging

OTTAWA, ON, July 13, 2023 /PRNewswire/ - Convergent Imaging Solutions, a leader in workflow optimized medical image fusion and nuclear medicine software, announced today that it has won the public tender for nuclear medicine processing software at Hôpital Montfort, in Ottawa, Canada.

Key Points: 
  • OTTAWA, ON, July 13, 2023 /PRNewswire/ - Convergent Imaging Solutions, a leader in workflow optimized medical image fusion and nuclear medicine software, announced today that it has won the public tender for nuclear medicine processing software at Hôpital Montfort, in Ottawa, Canada.
  • Combined with attractive pricing, the Convergent bundle was an easy selection", said Hélène Brunette, Manager of Imaging at Montfort.
  • In many cases, Convergent has modified and added new software features to help us optimize our imaging and reading workflow."
  • Founded in 2007, Convergent Imaging Solutions is based in Ottawa, Canada.

The multimodal Imaging Market is expected to display a steady growth of 5% due to the increasing incidences of chronic disorders | UnivDatos Market Insights

Retrieved on: 
Thursday, February 2, 2023
Carl Zeiss AG, PET/CT, Hospital, Canon Medical Systems Corporation, Disability, SPECT/CT, Midsayap Diagnostic Center and Hospital, Neurology, Oncology, Cardiology, PET/MRI, Research, PET-CT, Alzheimer's disease, Death, Milab, USD, WHO, DSM-IV codes, Disease, GE HealthCare, Growth, Multimodal, Human musculoskeletal system, Conditional sentence, Low back pain, Prevalence, COVID-19, Medical imaging, Cancer, Others, NOIDA

The multimodal imaging market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The multimodal imaging market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the Multimodal Imaging market.
  • The multimodal imaging market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the multimodal imaging market at the global and regional levels.

Spectrum Dynamics Medical and Kromek Group plc announce the introduction of the world's first digital SPECT/CT scanner using Kromek digital detectors for higher sensitivity and throughput.

Retrieved on: 
Monday, October 17, 2022
Quality of life, Nuclear medicine, Efficiency, KMK, Bomb, SPECT/CT, Algorithm, OEM, SPECT, Hospital, London Stock Exchange, Alzheimer's disease, Multimedia, AIM, Technology, Cancer, CT, CZT, Group, CEO, Face, London, Solution, View, Medical imaging, Television, Spectrum, CBRN

SARASOTA, Fla, Oct. 16, 2022 /PRNewswire/ -- Spectrum Dynamics Medical, a global leader in digital Nuclear Medicine SPECT and SPECT/CT scanners, and Kromek Group plc, a leading developer of high-performance detectors based on cadmium zinc telluride (CZT), today announced the integration of Kromek CZT detectors in Spectrum digital SPECT/CT products, the VERITON-CT 400 series.

Key Points: 
  • The 400 Series digital detector technology sets new standards with a 2-4 times improvement in energy range, system sensitivity, and energy resolution.
  • "Clinical users across the world provide us with feedback on the Nuclear Medicine challenges they face," said Spectrum Dynamics' CEO, Gilad Yoeli.
  • This enables enhanced image quality and breakthrough clinical capabilities in digital SPECT/CT," said Arnab Basu, CEO of Kromek Group plc.
  • In 2018, Spectrum Dynamics launched its multipurpose VERITON and the VERITON-CT SPECT/CT, the first ring-based 360 CZT digital SPECT/CT scanner.

Radiopharmaceuticals Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Adoption, Radiopharmaceutical, CDC, Cardiovascular disease, Therapy, Prevalence, Growth, Diagnosis, SPECT/CT, CAGR, Neoplasm, Centers for Disease Control and Prevention timeline, Lists of diseases, World Nuclear Association, Cancer, Center, Impact, US, Awareness, Conditional sentence, CVD, PET/CT, Immunotherapy, Death, COVID-19, Disease Control Priorities Project, 11C, Medical imaging, Medical device, Pharmaceutical industry, Speciality chemicals, Others

The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.

Key Points: 
  • The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.
  • The global radiopharmaceuticals market has been analyzed from four perspectives type, application, end user, and region.
  • Based on type, the global radiopharmaceuticals market is classified into:
    With the largest market share in 2021, the diagnostic radiopharmaceuticals segment dominates the global radiopharmaceutical market.
  • Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/radiopharmaceuticals...
    Based on application, the global radiopharmaceuticals market is segmented into:
    In terms of market share, the oncology segment will dominate the radiopharmaceuticals market in 2021.

Radiopharmaceuticals Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022
Adoption, Radiopharmaceutical, CDC, Cardiovascular disease, Therapy, Prevalence, Growth, Diagnosis, SPECT/CT, CAGR, Neoplasm, Centers for Disease Control and Prevention timeline, Lists of diseases, World Nuclear Association, Cancer, Center, Impact, US, Awareness, Conditional sentence, CVD, PET/CT, Immunotherapy, Death, COVID-19, Disease Control Priorities Project, 11C, Medical imaging, Medical device, Pharmaceutical industry, Speciality chemicals, Others

The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.

Key Points: 
  • The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.
  • The global radiopharmaceuticals market has been analyzed from four perspectives type, application, end user, and region.
  • Based on type, the global radiopharmaceuticals market is classified into:
    With the largest market share in 2021, the diagnostic radiopharmaceuticals segment dominates the global radiopharmaceutical market.
  • Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/radiopharmaceuticals...
    Based on application, the global radiopharmaceuticals market is segmented into:
    In terms of market share, the oncology segment will dominate the radiopharmaceuticals market in 2021.